Reviva pharmaceuticals announces global enrollment update for pivotal phase 3 recover study evaluating brilaroxazine for schizophrenia

- enrollment ongoing at multiple sites in the us and europe; site initiation in asia expected in november 2022 -

RVPH Ratings Summary

RVPH Quant Ranking